Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.42 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83489 | 0.98 | SKP2 (0.61) | SKP2HTR1ATLR8TYRCA2 | |
| SCHEMBL5830877 | 0.83 | HTR2A (0.53) | SKP2TLR8CA2HTR2A | |
| SCHEMBL2958383 | 0.83 | SKP2 (0.53) | SKP2HTR1ATLR8CA2HTR2A | |
| Hydrochloric Acid SCHEMBL11214753 | 0.82 | MAPT (0.46) | SKP2HTR1ATLR8TYRMAPK1 | |
| SCHEMBL8375841 | 0.82 | SKP2 (0.67) | SKP2HTR1ATLR8CA2SMN1; SMN2 | |
| SCHEMBL27705882 | 0.82 | SKP2 (0.45) | SKP2TLR8TYRHPGD | |
| SCHEMBL7204931 | 0.82 | SKP2 (0.71) | SKP2HTR1ACA2SMN1; SMN2HTR2A | |
| SCHEMBL8781871 | 0.82 | SKP2 (0.46) | SKP2CA2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29511379 | 0.82 | SKP2 (0.71) | SKP2HTR1ACA2SMN1; SMN2HTR2A | |
| SCHEMBL5830312 | 0.81 | HTR2A (0.47) | SKP2TLR8TYRSMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-8129545-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7982048-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | MAGNESIUM DIAGNOSTICS, INC. | 2011-01-27 | — | — | US | disclosed |
| US-7795450-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-7619097-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-7405311-B2 | Antagonist of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1355638-B1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6855826-B2 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-6664420-B2 | For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia | MAGNESIUM DIAGNOSTICS, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1355638-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | Magnesium Diagnostics, Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | MAGNESIUM DIAGNOSTICS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6455734-B1 | ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS | MAGNESIUM DIAGNOSTICS, INC. | 2002-09-24 | — | — | US | disclosed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110692-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20030040625-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | HTR1A 938/4885CA2 88/4885HTR2A 2016/4885 |
| US-20120142781-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20100048711-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20090030080-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20110021633-A1 | Antagonists of the Magnesium Binding Defect as Therapeutic Agents and Methods for Treatment of Abnormal Physiological States | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20060069259-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | ECE1, PLPBP, ECE2 | HTR1A 938/4885CA2 88/4885HTR2A 2016/4885 |
| US-20050096279-A1 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
| US-20110281923-A1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | PLPBP, ECE1, MCU | HTR1A 889/4885CA2 100/4885HTR2A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.